Can scans and blood predict CAR T-Cell success?
NCT ID NCT05422521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these tests could spot early signs of the cancer coming back or severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18FDG PET-CT scans and blood samples
What this could lead to
If successful, this could help doctors predict how well CAR T-cell therapy works for lymphoma patients and identify side effects earlier.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is exploratory and does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OR RELAPSED NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nice
Nice, 06000, France